The possible association between infertility, ovulation induction treatments and the incidence of cancer

CME Journal of Gynecologic Oncology

Volumn 9, Issue 3 PART 4, 2004, Pages 236-244

  Lerner Geva, Liat ^a  

^a GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

Author keywords

ART; Gynecologic malignancy; Infertility; IVF; Ovulation induction

Indexed keywords

CLOMIFENE CITRATE; CYCLOFENIL; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN;

BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER INCIDENCE; CANCER RISK; DISEASE ASSOCIATION; ENDOMETRIUM CARCINOMA; ENVIRONMENTAL FACTOR; FEMALE INFERTILITY; FERTILIZATION IN VITRO; GENE MUTATION; GONADAL AGENESIS; GONADOTROPIN BLOOD LEVEL; GONADOTROPIN RELEASE; HERITABILITY; HORMONAL CARCINOGENESIS; HUMAN; OVARY CANCER; OVARY CARCINOMA; OVARY HYPERSTIMULATION; OVULATION INDUCTION; REVIEW; RISK REDUCTION; UTERINE CERVIX CARCINOMA;

EID: 35748968780     PISSN: 12199087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Mosher WD, Pratt WF, Fecundity and infertility in the United States: incidence and trends. Fertil Steril 1991;56:192-198.
2. Friedlander M, de Souza P, Segelov E, Risk factors, epidemiology, screening and prognostic factors in female genital cancer. Curr Opin Oncol 1992;4:913-922.
3. Schenker JG, Laufer N, Weinstein D, Yarkoni S, Quintuplet pregnancies. Eur J Obstet Gynecol Reprod Biol 1980;10:257-268.
4. Hack M, Brish M, Serr DM, Insler V, Salomy M, Lunenfeld B, Outcome of pregnancy after induced ovulation. Follow-up of pregnancies and children born after clomiphene therapy. JAMA 1972;220:1329-1333.
5. Oelsner G, Blankstein J, Menashe Y, Serr DM, Tur-Kaspa I, Mashiach S, Ben-Rafael Z, The role of gonadotropins in the etiology of ectopic pregnancy. Fertil Steril 1989;52:514-516.
6. Bider D, Menashe Y, Oelsner G, Serr DM, Mashiach S, Ben-Rafael Z, Ovarian hyperstimulation syndrome due to exogenous gonadotropin administration. Acta Obstet Gynecol Scand 1989;68:511-514.
7. Schenker JG, Weinstein D, Ovarian hyperstimulation syndrome: A current survey. Fertil Steril 1978;30:255-268.
8. Navot D, Relou A, Birkenfeld A, Rabinowitz R, Brzezinski A, Margalioth EJ, Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynceol 1988;159:210-215.
9. Johannes CB, Caro JJ, Hartz SC, Marrs R, Adverse effects of ovulatory stimulants: A review. Assis Reprod Rev 1993;3:68-74.
10. Schenker JG, Ezra Y, Complications of assisted reproductive techniques. Fertil Steril 1994;61:411-422.
11. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, Cancer Incidence in Five Continents, Vol. VII: IARC Scientific Publications, No. 143, Lyon 1997.
12. Heintz AP, Hacker NF, Lagasse LD, Epidemiology and etiology of ovarian cancer: A review. Obstet Gynecol 1985;66:127-135.
13. Parazzini F, Franceschi S, La Vecchia C, Fasoli M, The epidemiology of ovarian cancer. Gynecol Oncol 1991;43:9-23.
14. Greene MH, Clark JW, Blayney DW, The epidemiology of ovarian cancer. Semin Oncol 1984;11:209-226.
15. Mori M, Harabuchi I, Miyake H, Casagrande JT, Henderson BE, Ross RK, Reproductive, genetic, and dietary risk factors for ovarian cancer. Am J Epidemiol. 1988;128:771-777.
16. West RO, Epidemiologic study of malignancies of the ovaries. Cancer. 1966;19:1001-1007.
17. Cramer DW, Welch WR, Scully RE, Wojciechowski CA, Ovarian cancer and talc: A case-control study. Cancer 1982;50:372-376.
18. McGowan L, Norris HJ, Hartge P Hoover R, Lesher L, Risk factors in ovarian cancer. Eur J Gynaecol Oncol 1988;9:195-199.
19. Joly DJ, Lilienfeld AM, Diamond EL, Bross ID, An epidemiologic study of the relationship of reproductive experience to cancer of the ovary. Am J Epidemiol 1974;99:190-209.
20. Lynch HT, Genetic risk in ovarian cancer. Gynecol Oncol 1992;46:1-3.
21. Schildkraut JM, Thompson WD, Familial ovarian cancer: a population-based case-control study. Am J Epidemiol 1988;128:456-466.
22. Lynch HT, Watson P, Lynch JF, Conway TA, Fili M, Hereditary ovarian cancer. Heterogeneity in age at onset. Cancer 1998;71(2 Suppl.):573-581.
23. Easton DF, Bishop DT, Ford D, Crockford GP, and the Breast Cancer Linkage Consortium, Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 1993;52:678-701.
24. Demopoulos RI, Seltzer V, Dubin N, Gutman E, The association of parity and marital status with the development of ovarian carcinoma: clinical implications. Obstet Gynecol 1979;54:150-5.
25. Risch HA, Weiss NS, Lyon JL, Daling JR, Liff JM, Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol. 1983;117:128-139.
26. Wu ML, Whittemore AS, Paffenbarger RJ, Jr., Sarles DL, Kampert JB, Grosser S, Jung DL, Ballon S, Hendrickson M, Mohle-Boetani J, Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use. Am J Epidemiol. 1988;128:1216-1227.
27. Gwinn ML, Lee NC, Rhodes PH, Layde PM, Rubin GL, Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol. 1990;43:559-568.
28. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development, The reduction in risk of ovarian cancer associated with oral-contraceptive use. N Engl J Med. 1987;316:650-655.
29. Rosenberg L, Shapiro S, Slone D, Kaufman DW, Helmrich SP, Miettinen OS, Stoley PD, Rosenshein NB, Schottenfeld D, Engle RL, Jr., Epithelial ovarian cancer and combination oral contraceptives. JAMA 1982;247:3210-3212.
30. Booth M, Beral V, Smith P, Risk factors for ovarian cancer: a case-control study. Br J Cancer. 1989;60:592-598.
31. Weiss NS, Measuring the separate effects of low parity and its antecedents on the incidence of ovarian cancer. Am J Epidemiol. 1988;128:451-455.
32. Hartge P, Schiffman MH, Hoover R, McGowan L, Lesher L, Norris HJ, A case-control study of epithelial ovarian cancer. Am J Obstet Gynecol 1989;161:10-16.
33. Parazzini F, La Vecchia C, Negri E, Gentile A, Menstrual factors and the risk of epithelial ovarian cancer. J Clin Epidemiol 1989;42:443-448.
34. Nasca PC, Greenwald P, Chorost S, Richart R, Caputo T, An epidemiologic case-control study of ovarian cancer and reproductive factors. Am J Epidemiol 1984;119:705-713.
35. Whittemore AS, Wu ML, Paffenbarger RJ, Jr., Sarles DL, Kampert JB, Grosser S, Jung DL, Ballon S, Hendrickson M, Mohle-Boetani J, Epithelial ovarian cancer and the ability to conceive. Cancer Res 1989;49:4047-4052.
36. Harlow BL, Weiss NS, Roth GJ, Chu J, Daling JR, Case-control study of borderline tumors: reproductive history and exposure to exogenous female hormones. Cancer Res 1988;48:5849-5852.
37. Kvale G, Heuch I, Nilssen S, Beral V, Reproductive factors and risk of ovarian cancer: a prospective study. Int J Cancer 1988;42:246-251.
38. Franceschi S, La Vecchia C, Helmrich SP, Mangioni C, Tognoni G, Risk factors for epithelial ovarian cancer in Italy. Am J Epidemiol 1982;115:714-719.
39. Fathalla MF, Incessant ovulation - a factor in ovarian neoplasia? Lancet 1971;ii:163.
40. Zajicek J, Prevention of ovarian cystomas by inhibition of ovulation: a new concept. J Reprod Med 1978;2:114.
41. Casagrande JT, Louie EW, Pike MC, Roy S, Ross RK, Henderson BE, «Incessant ovulation» and ovarian cancer. Lancet 1979;2:170-173.
42. Stadel BV, The etiology and prevention of ovarian cancer. Am J Obstet Gynecol 1975;123:772.
43. Daly MB, The epidemiology of ovarian cancer. In: Hematol./Oncol. Clinics of North America 1992: 729-738.
44. Bristow RE, Karlan BY, Ovulation induction, infertility and ovarian cancer risk. Fertil Steril 1996;66:499-507.
45. Cramer DW, Welch WR, Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. JNCI 1983;71:717-721.
46. Goldberg NB, Scully AL, Gonadal malignance in gonadal dysgenesis: Papillary pseudo-mucinous cystadenocarcinoma in a patient with Turner's syndrome. J Clin Endocrinol Metab 1967;27:341-347.
47. Miller DS, Teng N, Ballon S, Epithelial ovarian carcinoma in patient with intersex disorders: The role of pituitary gonadotropins in ovarian tumorigenesis. Gynecol Oncol 1986;24:299-308.
48. Mohle J, Whittemore A, Pike M, Darby S, Gonadotropins and ovarian cancer risk. JNCI 1985;75:178-179.
49. Stein DE, Santoro N, Infertility, gonadotropins and ovarian cancer. Infertil Manag 1997;8:289-303.
50. Bamford PN, Steele SJ, Uterine and ovarian carcinoma in a patient receiving gonadotrophin therapy. Case report. Br J Obstet Gynaecol 1982;89:962-964.
51. Atlas M, Menczer J, Massive hyperstimulation and borderline carcinoma of the ovary. A possible association. Acta Obstet Gynecol Scand 1982;61:261-263.
52. Ben-Hur H, Dgani R, Lancet M, Katz Z, Nissim F, Rosenman D, Ovarian carcinoma masquerading as ovarian hyperstimulation syndrome. Acta Obstet Gynecol Scand 1986;65:813-814.
53. Kulkarni R, McGarry JM, Follicular stimulation and ovarian cancer. Br Med J 1989;299:740.
54. Dietl J, Ovulation and ovarian cancer. Lancet 1991;338:445.
55. Goldberg GL, Runowicz CD, Ovarian carcinoma of low malignant potential, infertility, and induction of ovulation - is there a link? Am J Obstet Gynecol 1992;166:853-854.
56. Balasch J, Barri PN, Follicular stimulation and ovarian cancer? Hum Reprod 1993;8:990-996.
57. Karlan BY, Marrs R, Lagasse LD, Advanced-stage ovarian carcinoma presenting during infertility evaluation. Am J Obstet Gynecol 1994;171:1377-1378.
58. Salle B, de Saint Hilaire P, Devouassoux M, Gaucherand P, Rudigoz C, Another two cases of ovarian tumours in women who had undergone multiple ovulation induction cycles. Hum Reprod 1997;12:1732-1735.
59. Bandera CA, Cramer DA, Friedman AJ, Sheets EE, Fertility therapy in the setting of a history of invasive epithelial ovarian cancer. Gynecol Oncol 1995;58:116-118.
60. Whittemore AS, Harris R, Itnyre J, Halpern J, Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. I. Methods. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1175-1183.
61. Whittemore AS, Harris R, Itnyre J, Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1184-1203.
62. Whittemore AS, Harris R, Itnyre J, Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1212-1220.
63. Harris R, Whittemore AS, Itnyre J, Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol. 1992;136:1204-1211.
64. Ron E, Lunenfeld B, Menczer J, Blumstein T, Katz L, Oelsner G, Serr D, Cancer incidence in a cohort of infertile women. Am J Epidemiol 1987;125:780-790.
65. Shu XO, Brinton LA, Gao YT, Yuan JM, Population-based case-control study of ovarian cancer in Shanghai. Cancer Res 1989;49:3670-3674.
66. Spirtas R, Kaufman SC, Alexander NJ, Fertility drugs and ovarian cancer: red alert or red herring? Fertil Steril 1993;59:291-293
67. Cohen J, Forman R, Harlap S, Johannisson E, Lunenfeld B, de Mouzon J, Pepperell R, Tarlatzis B, Templeton A, IFFS Experts Group Report on the Whittemore study related to the risk of ovarian cancer associated with the use of fertility agents. Hum Reprod 1993;8:996-999.
68. Walters DE, Ovarian cancer and pregnancy: comment on a paper by Whittemore. Fertil Steril 1994;61:239-242.
69. Shoham Z, Epidemiology, etiology and fertility drugs in ovarian epithelial carcinoma: Where are we today? Fertil Steril 1994;62:433-448.
70. Finkler RS, Evaluation of hormonal and radiation therapy in 190 cases of functional sterility and secondary amenorrhea. J Obstet Gynecol 1949;58:559-564.
71. Ryberg E, Gonadotropic hormones in gynecologic therapy. Ugesk F Laeger 1939;101:375-382.
72. Swyer GI, Induction of ovulation in the human - older and newer approaches. Proc R Soc Med 1963;56:39-46.
73. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG, Ovarian tumors in a cohort of infertile women. N Engl J Med 1994;331:771-776.
74. Willemsen W, Kruitwagen R, Bastiaans B, Hanselaar T, Rolland R, Ovarian stimulation and granulosa-cell tumors. Lancet 1993;341:986-988.
75. Del Priore G, Robischon K, Phipps WR, Risk of ovarian cancer after treatment for infertility. N Engl J Med 1995;332:1300.
76. Franceschi S, La Vecchia C, Negri E, Guarneri S, Montella M, Conti E, Parazzini F, Fertility drugs and risk of epithelial ovarian cancer in Italy. Hum Reprod 1994;9:1673-1675.
77. Shushan A, Elchalal U, Paltiel O, Peretz T, Ischovich J, Schenker JG, Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 1996;65:13-18.
78. Mosgaard BJ, Schou G, Lidegaard O, Nyboe Anderson A, Kjaer SK, Infertility, fertility drugs and invasive ovarian cancer: a case-control study. Fertil Steril 1997;67:1005-1012.
79. Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J, Oelsner G, Freedman L, Mashiach S, Lunenfeld B, Cancer incidence in a cohort of infertile women. Am J Epidemiol 1998; 147:1038-1042.
80. Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A, Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil Steril 1999;71:853-859.
81. Ness RB, Cramer DW, Goodman MT, Kruger Kjaer S, Mallin K, Jul Mosgaard B, Purdie DM, Risch HA, Vergona R, Wu AH, Infertility, fertility drugs, and ovarian cancer: A pooled analysis of case-control studies. Am J Epidemiol 2002;155:217-224.
82. Lerner-Geva L, Blumstein T, Rabinovici J, Mashiach S, Potashnik G, Lunenfeld E, Schenker JG, Shushan A, Beith Y, Cohen I, Ayalon D, Vagman I, Novikov I, Olmar L, Freedman L, Lunenfeld B, Kuller LH, Green MS, Modan B. Infertility, ovulation induction treatments and ovarian cancer - is there an association? 2004 (Submitted).
83. Couch FJ, DeShano ML, Blackwood A, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL, BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997;336:1409-1415.
84. Westhoff C, Infertility and breast cancer. Gynecol Oncol 1996;60:1-2.
85. Gross J, Modan B, Bertini B, Spira O, de Waard F, Thijssen JHH, Vestergaard P, Relationship between steroid excretion patterns and breast cancer incidence in Israeli women of various origins. JNCI 1977;59:7-11.
86. Harlap S, Oral contraceptives and breast cancer. J Reprod Med 1991;36:374-395.
87. Wren B, Hormonal therapy and genital tract cancer. Curr Opin Obstet Gynecol 1996;8:38-41.
88. La Vecchia C, Negri E, Franceschi S, Talamini R, Amadori D, Filiberti R, Conti E, Montella M, Veronesi A, Parazzini F, Oral contraceptives and breast cancer: a cooperative Italian study. Int J Cancer 1995;60:163-167.
89. Cowan LD, Gordis L, Tonascia JA, Jones GS, Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol 1981;114:209-217.
90. Coulam CB, Annegers JF, Kranz JS, Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 1983;61:403-407.
91. Gammon M, Thompson WD, Infertility and breast cancer: A population-based case-control study. Am J Epidemiol 1990;132:708-716.
92. Brinton LA, Melton LJ, III, Malkasian GD, Jr., Bond A, Hoover R, Cancer risk after evaluation for infertility. Am J Epidemiol 1989;129:712-722.
93. Sutherland RL, Watts CKW, Hall RE, Ruenitz PC, Mechanisms of growth inhibition by non-steroidal anti-estrogens in human breast cancer cells. J Steroid Biochem 1987;27:891-897.
94. Brzezinski A, Peretz T, Mor-Yosef S, Schenker JG, Ovarian stimulation and breast cancer: Is there a link? Gynecol Oncol 1994;52:292-295.
95. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG, Risk of breast cancer in a cohort of infertile women. Gynecol Oncol 1996;60:3-7.
96. Braga C, Negri E, La Vecchia C, Parazzini F, Dal Maso L, Franceschi S, Fertility treatment and risk of breast cancer. Hum Reprod 1996;11:300-303.
97. Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL. Cancer incidence following treatment for infertility at a clinic in the UK. Human Reprod 2002;17:2209-2213.
98. Burkman RT, Tang MC, Malone KE, Marchbanks PA, McDonald JA, Folger SG. Infertility and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Women's Contraceptive and Reproductive Experiences Study. Fertil Steril 2003;79:844-854.
99. Ludwig H, Women and cancer. Int J Gynecol Obstet 1994;46:195-202.
100. Kelsey JL, LiVolsi VA, Holford TR, Fischer DB, Mostow ED, Schwartz PE, O'Connor T, White C, A case-control study of cancer of the endometrium. Am J Epidemiol 1982;116:333-342.
101. Vessey MP, Painter R, Endometrial and ovarian cancer and oral contraceptives-finding in a large cohort study. Br J Cancer 1995;71:1340-1342.
102. Levi F, Franceschi S, Negri E, La Vecchia C, Dietary factors and the risk for endometrial cancer. Cancer 1993;71:3575-3581.
103. Escobedo LG, Lee NC, Peterson HB, Wingo PA, Infertility-associated endometrial cancer risk may be limited to specific subgroups of infertile women. Obstet Gynecol 1991;77:124-128.
104. Smith DC, Prentice R, Thompson DJ, Herrman WL, Association of exogenous estrogens and endometrial cancer. N Engl J Med 1975;293:1164-1167.
105. Mack TM, Pike MC, Henderson BE, Pfeffer RI, Gerkins VR, Arthur M, Brown SE, Estrogens and endometrial cancer in retirement community. N Engl J Med 1976;294:1262-1267.
106. Antunes CMF, Stolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, Burnett L, Rutledge MA, Pokempner M, Garcia R, Endometrial cancer and estrogen use. N Engl J Med 1979;300:9-13.
107. Cancer in Israel, State of Israel Ministry of Health, Israel Cancer Registry, 1996.
108. Schiff M, Miller J, Masuk M, van Asselt King L, Altobelli KK, Wheeler CM, Becker TM, Contraceptive and reproductive risk factors for cervical intraepithelial neoplasia in American Indian women. Int J Epidemiol 2000;29:983-990.
109. Rossing MA, Moore DE, Daling JR, Self SG, Weiss NS, In situ and invasive cervical carcinoma in a cohort of infertile women. Fertil Steril 1996;65:19-22.
110. Zanetti R, Franceschi S, Rosso S, Bidoli E, Colonns S, Cutaneous malignant melanoma in females: the role of hormonal and reproductive factors. Int J Epidemiol 1990;19:522-526.
111. Holly EA, Weiss NS, Liff JM, Cutaneous melanoma in relation to exogenous hormones and reproductive factors. JNCI 1983;70:827-831.
112. Holman CDJ, Armstrong BK, Heenan PJ, Cutaneous malignant melanoma in women: exogenous sex hormones and reproductive factors. Br J Cancer 1984;50:673-680.
113. Gallaghar RP, Elwood JM, Hill GB, Coldman AJ, Threlfall WJ, Spinelli JJ, Reproductive factors, oral contraceptives and risk of malignant melanoma: Western Canada Melanoma Study. Br J Cancer 1985;52:901-907.
114. Osterlind A, Tucker MA, Stone BJ, Jensen OM, The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women. Int J Cancer 1988;42:821-824.
115. Kuppens E, Bergman W, Welvaart K, Bruijn JA, Scheffer E, Multiple primary melanomas in a patient with familial-type DNS during clomiphene-induced pregnancy. Melanoma Res 1992;2:71-74.
116. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG, Risk of cutaneous melanoma in a cohort of infertile women. Melanoma Res 1995;5:123-127.
117. Carter ME, Joyce DN, Ovarian carcinoma in a patient hyperstimulated by gonadotropin therapy for in vitro fertilization: a case report. J In-Vitro Fert Embryo Transf. 1987;4:126-128.
118. Nijman HW, Burger CW, Baak JP, Schats R, Vermorken JB, Kenemans P, Borderline malignancy of the ovary and controlled hyperstimulation, a report of 2 cases. Eur J Cancer 1992;28A:1971-1973.
119. Lopes P, Mensier A, Laurent FX, Laborde I, Sagot P, Jean M, Barriere P, Ovarian cancer and medically assisted reproductive. Eur J Obstet Gynecol Reprod Biol 1993;51:171-173.
120. Grimbizis G, Tarlatzis BC, Bontis J, Miliaras D, Lagos S, Pournaropoulos F, Mantalenakis S, Two cases of ovarian tumors in women who had undergone multiple ovarian stimulation attempts. Hum Reprod 1995;10:520-523.
121. Venn A, Watson L, Lumley J, Giles G, King C, Healy D, Breast and ovarian cancer incidence after infertility and in-vitro fertilization. Lancet 1995;346:995-1000.
122. Venn A, Watson L, Bruinsma F, Giles G, Healy D, Risk of cancer after use of fertility drugs with in-vitro fertilization. Lancet 1999;354:1586-1590.
123. Laing RW, Glaser MG, Barret GSA, A case of breast carcinoma in association with in-vitro fertilization. J R Soc Med 1989;82:503.
124. Bolton PM, Bilateral breast cancer associated with clomiphene . Lancet. 1977;2:1952.
125. Arbour L, Narod S, Glendon G, Pollak M, Seymour R, Miner L, Leung P, In-vitro fertilization and family history of breast cancer. Lancet 1994;344:610-611.
126. Dor J, Lerner-Geva L, Rabinovici J, Chetrit A, Levran D, Lunenfeld B, Mashiach S, Modan B, Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril 2002;77:324-327.
127. Lerner-Geva L, Geva E, Lessing JB, Chetrit A, Modan B, Amit A, The possible association between in-vitro fertilization treatments and cancer development. Int J Gynecol Cancer 2003; 13:33-27.
128. Edwards RG, Steptoe PC, Purdy JM, Establishing full-term human pregnancies using cleaving embryos grown in-vitro. Br J Obstet gynecol 1980;87:737-768.